Sign up to save your podcasts
Or
Share Oncotarget
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Oncotarget
By Oncotarget PodcastScience
Oncotarget episodes
- Bacterial Therapy Experiments in Prostate CancerOver the past few decades, numerous studies have emerged using the promising strategy of bacteria as vehicles to deliver drugs or genes in tumor‐targeted therapies. Researchers say that bacterial cancer therapy may be able to overcome some of the limitations that conventional cancer therapy is stunted by, including the development of drug resistance.In a 2020 study, researchers—from Yale University, the University of Missouri, Harry S. Truman Memorial Veterans Hospital, Cancer Research Center in Missouri, and DeSales University—investigated a tumor-targeting Salmonella typhimurium strain of bacteria (CRC2631) in prostate cancer-positive mouse-models and evaluated its toxicity, targeting ability and genetic stability. Their trending paper was published by Oncotarget and entitled, “Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model.”“Here, we report the toxicological and in vivo tumor-targeting profiles of CRC2631 in the syngeneic and autochthonous mouse model of aggressive prostate cancer, TRAMP (Transgenic Adenocarcinoma of Mouse Prostate).”Full blog - https://www.oncotarget.org/2021/01/21/bacterial-therapy-experiments-in-prostate-cancer/Press release - https://www.oncotarget.com/news/pr/evaluations-in-the-tramp-prostate-cancer-model/Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27769DOI - https://doi.org/10.18632/oncotarget.27769Full text - https://www.oncotarget.com/article/27769/text/Correspondence to - Yves C. Chabu - [email protected]Keywords - salmonella, cancer targeting, prostate cancer, immunotherapy, TRAMPAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact1800922095710 min
- Benzophenone-3 Promotion of Mammary Tumorigenesis is Diet-dependentOncotarget published "Benzophenone-3 promotion of mammary tumorigenesis is diet-dependent" which reported that Benzophenone-3 is a putative endocrine disrupting chemical and common ingredient in sunscreens.Although benzophenone-3 seemed protective on low-fat diet, spindle cell tumors arising in these mice showed increased proliferation and decreased apoptosis. This points to a need for further studies of benzophenone-3 in both animal models and humans as a potential breast cancer risk factor, as well as a more general need to evaluate endocrine disrupting chemicals in varying dietary contexts.Dr. Richard C. Schwartz and Dr. Sandra Z. Haslam, both from The Michigan State University said, "Ovarian hormones are strongly implicated in the etiology of breast cancer."Putative endocrine disrupting chemicals, particularly estrogenic chemicals, have emerged as suspects in environmental promotion of breast cancer. Environmental EDCs have the potential to act as agonists or antagonists in critical hormonally regulated processes, such as mammary gland development and mammary tumorigenesis - this warrants evaluation of their potential in promoting breast cancer.More recently, BP-3 was demonstrated to have pathological effects on coral. Although BP-3 has a very short half-life, its presence is widespread in human urine, in as much as 98% of the general U.S. population.A recent preliminary study found plasma concentrations greater than 0.5 ng/mL among a small human cohort using heavy topical applications of commercial sunscreens. The present study examined the interaction of BP-3 with HFD on mammary tumorigenesis in BALB/c mice, using the Trp53-null transplantation model. A level of BP-3 exposure was used that yielded levels in murine urine similar to that observed in humans subjected to heavy topical exposure of BP-3-containing commercial sunscreen. These authors found that BP-3 had complex effects that were dependent upon dietary regimen and tumor histopathology.The Schwartz/Haslam Research Team concluded in their Oncotarget Research Output that unlike several earlier studies that found rather minimal BP-3 activity in vivo in rodents with doses higher than those in the current study: 1500 mg/kg BW/d; 1000 mg/kg BW/d; 150 mg/kg BW/d, these authors tumorigenesis experiments showed significant effects at 70 mg/kg BW/d. This dosage elicits levels of BP-3 excretion in urine similar to that observed in humans with heavy topical application of BP-3-containing sunscreen. Furthermore, their initial experiments in wild type BALB/c mice found significant effects on mammary epithelial proliferation at only 7 mg/kg BW/d. These observations suggest caution in the use of BP-3-containing sunscreens.DOI - https://doi.org/10.18632/oncotarget.27831Full text - https://www.oncotarget.com/article/27831/text/Correspondence to - Richard C. Schwartz - [email protected] and Sandra Z. Haslam - [email protected]Keywords - oxybenzone, benzophenone-3, mammary tumorigenesis, dietary animal fat, breast cancerAbout OncotargetOncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetLinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact18009220957x105Copyright © 2021 Impact Journals, LLCImpact Journals is a registered trademark of Impact Journals, LLC10 min
- New Study: Vaccine Enhances Breast Cancer TreatmentThe most common type of breast cancer in the United States is HR+/HER2− breast cancer. Patients with HR+/HER2− breast cancer often face the threat of distant recurrence—long after the completion of their treatment. Previous studies have found that high levels of tumor infiltrating lymphocytes (TILs) were associated with improved outcomes and recurrence-free survival in patients with HR+/HER2− breast cancer. These studies, and many others, have prompted researchers to further develop and test cancer vaccines in an effort to elicit anti-tumor immune responses in these patients.“Therefore, a rational combination therapy that enhances the immune-stimulatory properties of NAC [neoadjuvant chemotherapy], can provide long-term survival benefits for this patient population.”Researchers from University of Arkansas for Medical Sciences, University of Texas Southwestern, Highlands Oncology Group, and Université Claude Bernard Lyon 1 conducted a new single-arm Phase Ib clinical trial. Early-stage HR+/HER2− breast cancer patients were treated with carbohydrate-mimetic peptides, the P10s-PADRE vaccine, in combination with chemotherapy treatments. Their paper was chosen as the cover of Oncotarget’s Volume 12, Issue 22, and entitled, “P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses.”“The main objective of our study was to determine an appropriate schedule to be used for adding the P10s-PADRE vaccine to cancer chemotherapy in the neoadjuvant setting considering the ability of the vaccine to elicit adequate antibody response.”Full blog - https://www.oncotarget.org/2021/10/27/new-study-vaccine-enhances-breast-cancer-treatment/Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28083DOI - https://doi.org/10.18632/oncotarget.28083Full text - https://www.oncotarget.com/article/28083/text/Correspondence to - Behjatolah Monzavi-Karbassi - [email protected]Keywords - cancer vaccine, peptide mimotopes, combination therapy, breast cancerAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209577 min
- Table of Contents: Volume 12, Issue #22Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 22.https://www.oncotarget.com/archive/v12/i22/Research Paper (Cover) - “P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses”https://doi.org/10.18632/oncotarget.28083Research Paper - “Dishevelled-1 DIX and PDZ domain lysine residues regulate oncogenic Wnt signaling”https://doi.org/10.18632/oncotarget.28089Research Paper - “THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma”https://doi.org/10.18632/oncotarget.28099Research Paper - “Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in situ hybridization”https://doi.org/10.18632/oncotarget.28092Review - “Emerging approaches of wound healing in experimental models of high-grade oral mucositis induced by anticancer therapy” https://doi.org/10.18632/oncotarget.28091Editorial - “Future directions for immunotherapy in meningioma treatment”https://doi.org/10.18632/oncotarget.27994 (PDF Download)Editorial - “Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer”https://doi.org/10.18632/oncotarget.28007 (PDF Download)Keywords - cancer vaccine, dishevelled (DVL), next-generation sequencing (NGS), oral mucositis, meningioma, immunotherapy, HER2 low, pancreatic cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, cancer, science, research, oncologyAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetLinkedIn - https://www.linkedin.com/company/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/oncotargetyoutubePinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/OncotargetOncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnlsMedia Contact180092209577 min
- EMT Resistance in Cancer Cells and Two Potential CausesCancer cells have been known to use sagacious methods of evading apoptosis and mysteriously overcoming powerful anti-cancer therapies. One such method of evasion has recently been identified as the process of epithelial-mesenchymal transition (EMT) and its reverse process, mesenchymal-epithelial transition (MET). These transitions enable epithelial cells (structural/fixed) to gain mesenchymal cell (differentiating/mobile) functions, and vice versa. Researchers believe that epithelial-mesenchymal plasticity (EMP) allows cancers to become therapy resistant, determines cancer aggressiveness and allows metastatic cancer to mobilize and spread.“Such dynamic and reversible switching can help tumor cells to overcome various challenges during disease progression such as anoikis, and assaults by the immune system.”These processes and their characterization in cancer have been studied, however, questions remain about their molecular determinants and degree of reversibility, or irreversibility, in different cell populations and environments. To further elucidate EMT, researchers from Rice University, Northeastern University and the Indian Institute of Science used mechanistic mathematical models to identify possible mechanisms that may drive EMT response to an EMT-inducing signal in a given isogenic cell population. Their paper was published by Oncotarget in 2020, and entitled, “Epigenetic feedback and stochastic partitioning during cell division can drive resistance to EMT.”Full blog - https://www.oncotarget.org/2021/10/21/emt-resistance-in-cancer-cells-and-two-potential-causes/Press release - https://www.oncotarget.com/news/pr/epigenetic-feedback-and-stochastic-partitioning-can-drive-resistance-to-emt/Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27651DOI - https://doi.org/10.18632/oncotarget.27651Full text - https://www.oncotarget.com/article/27651/text/Correspondence to - Herbert Levine - [email protected] and Mohit Kumar Jolly - [email protected]Keywords - epithelial-mesenchymal transition, mesenchymal-epithelial transition, GRHL2, epigenetics, asymmetric cell divisionAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetYouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209578 min
- New Study: ATR Inhibition Reverses Chemo-Resistance in Subset of CellsTemozolomide (TMZ) is a powerful chemotherapeutic drug that is currently approved to treat brain cancer (glioblastoma, GBM) and advanced melanoma. TMZ has a remarkably precise molecular target—the O-6 position of guanine—and is capable of inducing DNA damage. This prodrug can elicit many responses in a variety of cancer cells, including cell death, autophagy and senescence. At present, there are over 300 clinical trials evaluating the efficacy of TMZ in combination with other agents in solid tumors. At least 25% of these trials include testing the efficacy of TMZ in breast, pancreatic, colorectal and lung cancers.“Low MGMT levels in other types of cancer have resulted in the consideration of TMZ as a potential therapy beyond glioblastoma and melanoma.”However, not all patients benefit from TMZ treatment, despite presenting with biomarkers known to predict TMZ treatment response, such as low O-6-Methylguanine-DNA methyltransferase (MGMTlow) and proficient DNA mismatch repair (MMRproficient). Researchers have found in some patients that the clinical efficacy of TMZ is hindered by inherent and acquired mechanisms of resistance.In 2021, a team of researchers from Leidos Biomedical Research Inc. (the current operations and technical support contractor for the Frederick National Laboratory for Cancer Research) and the National Institutes of Health’s National Cancer Institute conducted a new study on TMZ. In an attempt to overcome TMZ resistance, they examined the in vitro and in vivo anti-tumor efficacy of TMZ when combined with ataxia telangiectasia and Rad3 related inhibitors (ATRi) and a wide variety of other inhibitor drugs. Their paper was published as the cover of Oncotarget’s Volume 12, Issue 21, and entitled, “ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide.”Full blog - https://www.impactjournals.com/journals/blog/oncotarget/new-study-atr-inhibition-reverses-chemo-resistance-in-subset-of-cells/Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28090DOI - https://doi.org/10.18632/oncotarget.28090Full text - https://www.oncotarget.com/article/28090/text/Correspondence to - Annamaria Rapisarda - [email protected]Keywords - TMZ, MMR, ATR, HR, REV3LAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetYouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209578 min
- Table of Contents: Volume 12, Issue #21Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 21.https://www.oncotarget.com/archive/v12/i21/Priority Research Paper (Cover) - “ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide”https://doi.org/10.18632/oncotarget.28090Research Paper - “Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab”https://doi.org/10.18632/oncotarget.28086Research Paper - “Luminescence complementation technology for the identification of MYC:TRRAP inhibitors”https://doi.org/10.18632/oncotarget.28078Research Paper - “TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan” https://doi.org/10.18632/oncotarget.28073Research Paper - “The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey” https://doi.org/10.18632/oncotarget.28076Research Paper - “Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma”https://doi.org/10.18632/oncotarget.28069Research Paper - “Trends in oligomannosylation and α1,2-mannosidase expression in human cancers” https://doi.org/10.18632/oncotarget.28064Research Paper - “TP53 mutations determined by targeted NGS in breast cancer: a case-control study” https://doi.org/10.18632/oncotarget.28071Research Paper - “Association of four genetic variants with colorectal cancer in Kazakhstan population” https://doi.org/10.18632/oncotarget.28070Editorial - “Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy?”https://doi.org/10.18632/oncotarget.27987 (PDF Download)Research Perspective - “Neddylation and anti-tumor immunity”https://doi.org/10.18632/oncotarget.28019Keywords - ATR, cancer immunotherapy, drug discovery, comprehensive genomic profiling, glioblastoma, oligomannose, TP53 mutations, head and neck cancer, neddylation, breast cancer, colorectal cancer, multiple myeloma (MM), cancer, science, research, oncologyAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetLinkedIn - https://www.linkedin.com/company/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/oncotargetyoutubePinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/OncotargetOncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnlsMedia Contact180092209579 min
- Exploration of Gene Editing in the Tumor SettingRevelations in gene editing have made it possible to tinker in the vast human epigenome and to potentially alter the projection of diseases, including cancer. DNA methylation is an epigenetic mechanism that marks the regulation of gene expression. P53 is a highly-mutated gene in many patients with various cancerous tumors. The insulin-like growth factor binding protein 2 (IGFBP2) is an oncogene directly regulated through p53-mediated transcription. In tumorigenesis, this protein has both tumor-promoting and -suppressing functions.“In this study, we will focus on the insulin-like growth factor binding protein 2 (IGFBP2), a recently discovered multitasked gene regulated by DNA methylation which has also been reported to function both as a tumor-promoting and -suppressing gene.”Researchers from The Netherlands Cancer Institute in Amsterdam conducted a study using CRISPR/Cas9 technology and IGFBP2 to learn about the process of DNA methylation in various tumor settings. Their trending research paper was published in Oncotarget in 2021, and entitled, “Diverse transcriptional regulation and functional effects revealed by CRISPR/Cas9-directed epigenetic editing.”“Here, we have taken advantage of CRISPR/dCas9 technology adapted for epigenetic editing through site-specific targeting of DNA methylation to characterize the transcriptional changes of the candidate gene and the functional effects on cell fate in different tumor settings.”Full blog - https://www.impactjournals.com/journals/blog/oncotarget/exploration-of-gene-editing-in-the-tumor-setting/Press release - https://www.oncotarget.com/news/pr/crispr-cas9-directed-epigenetic-editing/Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28037DOI - https://doi.org/10.18632/oncotarget.28037Full text - https://www.oncotarget.com/article/28037/text/Correspondence to - Miguel Vizoso - orcid.org/0000-0002-9992-2851 and Jacco van Rheenen - [email protected]Keywords - targeted DNA methylation, CRISPR/Cas9-based system, IGFBP2, epithelial-to-mesenchymal transitionAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetLinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209577 min
- Unconventional Method Effectively Targets NSCLCThe mammalian target of rapamycin (mTOR) operates within two distinct protein complexes—mTOR complex 1 (mTORC1) and complex 2 (mTORC2). These protein complexes are not yet fully understood, as they were only recently identified in humans in 1994. What researchers do know is that mTORC1 is involved in the regulation of many cellular processes and is a key mediator of cell growth and proliferation. mTORC1 is activated by growth factor receptor signals through the PI3K–AKT and RAS–ERK mitogen-activated protein kinase (MAPK) pathways.The PI3K/AKT/mTOR pathway may be an efficacious target in the treatment of patients with non-small cell lung cancer (NSCLC). This theory is based on the identification of particular gene mutations in NSCLC that are associated with the PI3K/AKT/mTOR pathway. However, previous studies have not yet succeeded in defining an effective monotherapy or combination of therapies that targets this pathway while improving NSCLC patient outcome.Researchers from Institut Curie, PSL University, Xentech, BioPôle Alfort, Hôpital Foch, and Centre Léon Bérard designed a study using a new methodology to test treatment combinations based on specific targets identified as biomarkers of resistance to PI3K-targeting treatments, and not based on the NSCLC mutations themselves. Their trending research paper was published by Oncotarget in 2021 and entitled, “High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC.”Full blog - https://www.oncotarget.org/2021/09/30/trending-with-impact-unconventional-method-effectively-targets-nsclc/Press release - https://www.oncotarget.com/news/pr/mtorc1-and-plk1-inhibition-in-adenocarcinoma-nsclc/Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27930DOI - https://doi.org/10.18632/oncotarget.27930Full text - https://www.oncotarget.com/article/27930/text/Correspondence to - Didier Decaudin - [email protected]Keywords - NSCLC, Pi3K signalling pathway, mTORC1, RAD001 (everolimus), PLK1About OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetYouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209578 min
- New Study: Protein Analysis Reveals Novel Role of Enzyme In CancerA small regulatory protein can be found not only in all humans, animals, plants and fungi, but in each and every eukaryotic cell. Following the discovery of these ubiquitous proteins in 1974, researchers aptly named them ubiquitin. Enzymes and/or ligases (enzymes that catalyze the formation of chemical bonds), allow ubiquitins to bind to substrate proteins. This process, known as ubiquitination, can initiate or prevent protein interactions, denote them for degradation and alter their activity and cellular location.Aberrant ubiquitination may play an important role in tumorigenesis. At the core of solid tumors, hypoxia-inducible factor 1α (HIF-1α) is induced (by hypoxia) and allows cancer cells to adapt to the lack of oxygen. The accumulation of HIF-1α can also transcribe a number of genes well-known to be involved in cancer. Therefore, HIF-1α is an attractive, albeit difficult-to-pinpoint, therapeutic target in cancer. Researchers—from Brown University and Lifespan Cancer Institute—previously observed the stabilization of HIF-1α by the protein coding gene cyclin-dependent kinases CDK1. They further proposed that CDK4 may also be an HIF-1α stabilizer. However, the mechanism of HIF-1α’s regulation by CDK4 has yet to be fully elucidated.“Till now, development of therapies targeting HIF-1α remains hindered. Therefore, it is imperative to explore the mechanism of HIF-1α regulation in cancer cells and investigate new possibilities to therapeutically target HIF-1 signaling.”In 2021, the same team conducted a new study further investigating the molecular mechanisms of HIF-1α destabilization by CDK1 or CDK4/6 inhibitors in colorectal cancer. Their priority research paper was published as the cover of Oncotarget’s Volume 12, Issue 20, and entitled, “Identification of Smurf2 as a HIF-1α degrading E3 ubiquitin ligase.”Full blog - https://www.oncotarget.org/2021/09/30/new-study-protein-analysis-reveals-novel-role-of-enzyme-in-cancer/Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28081DOI - https://doi.org/10.18632/oncotarget.28081Full text - https://www.oncotarget.com/article/28081/text/Correspondence to - Wafik S. El-Deiry - [email protected]Keywords - Smurf2, CDK4/6 inhibition, HIF1alpha, hypoxia, cancer therapyAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetYouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209577 min
About Oncotarget
From the publisher's feed
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/